|
2016 |
Discovery of Stable Non-opioid Dynorphin A Analogues Interacting at the Bradykinin Receptors for the Treatment of Neuropathic Pain. |
Frank Porreca, PhD |
|
2012 |
Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy. |
John M. Streicher, PhD |
|
2015 |
Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain. |
Victor Hruby, Ph.D., Tally Largent-Milnes, PhD, Frank Porreca, PhD, Todd Vanderah, PhD |
|
2022 |
Discovery of Levesquamide B through Global Natural Product Social Molecular Networking. |
Christopher Cartmell |
|
2014 |
Discovery of amphipathic dynorphin A analogues to inhibit the neuroexcitatory effects of dynorphin A through bradykinin receptors in the spinal cord. |
Victor Hruby, Ph.D., Josephine Lai , Ph.D., Frank Porreca, PhD, Todd Vanderah, PhD |
|
2011 |
Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies. |
Tally Largent-Milnes, PhD, Frank Porreca, PhD, Todd Vanderah, PhD |
|
2015 |
Discovery of 5-substituted tetrahydronaphthalen-2yl-methyl with N-phenyl-N-(piperidin-4-yl)propionamide derivatives as potent opioid receptor ligands. |
Tally Largent-Milnes, PhD, Frank Porreca, PhD, Todd Vanderah, PhD |
|
2012 |
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues. |
John M. Streicher, PhD |
|
2012 |
Differential responses of progesterone receptor membrane component-1 (Pgrmc1) and the classical progesterone receptor (Pgr) to 17β-estradiol and progesterone in hippocampal subregions that support synaptic remodeling and neurogenesis. |
Roberta Diaz Brinton, Ph.D |
|
2014 |
Differential regulation of collapsin response mediator protein 2 (CRMP2) phosphorylation by GSK3ß and CDK5 following traumatic brain injury. |
|
|
2014 |
Differential neuroprotective potential of CRMP2 peptide aptamers conjugated to cationic, hydrophobic, and amphipathic cell penetrating peptides. |
|
|
2008 |
Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. |
|
|
2011 |
Development of potent μ and δ opioid agonists with high lipophilicity. |
Frank Porreca, PhD, Todd Vanderah, PhD |
|
2021 |
Development of N,O-Carboxymethyl Chitosan-Starch Biomaterial Inks for 3D Printed Wound Dressing Applications. |
Christopher Cartmell |
|
2013 |
Development of functionally selective, small molecule agonists at kappa opioid receptors. |
John M. Streicher, PhD |
|
2021 |
Development of a microbe domestication pod (MD Pod) for in situ cultivation of micro-encapsulated marine bacteria. |
Christopher Cartmell |
|
2020 |
Development of 3D Printed Drug-Eluting Scaffolds for Preventing Piercing Infection. |
Christopher Cartmell |
|
2002 |
Development and molecular characterization of HCT-116 cell lines resistant to the tumor promoter and multiple stress-inducer, deoxycholate. |
|
|
2023 |
Development and evaluation of a pre-clerkship spiral curriculum: data from three medical school classes. |
Todd Vanderah, PhD |
|
2019 |
Development and Characterization of An Injury-free Model of Functional Pain in Rats by Exposure to Red Light. |
Mohab M. Ibrahim, PhD, MD, Frank Porreca, PhD, Todd Vanderah, PhD |
|
1995 |
Detecting differences in 5-methylcytosine using restriction enzyme isoschizomers: an endogenous control for complete digestion. |
|
|
2015 |
Design, synthesis, and biological evaluation of a series of bifunctional ligands of opioids/SSRIs. |
|
|
2022 |
Design, Physicochemical Characterization, and In Vitro Permeation of Innovative Resatorvid Topical Formulations for Targeted Skin Drug Delivery. |
Sally Dickinson, Ph.D. |
|
2015 |
Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives. |
Victor Hruby, Ph.D., Tally Largent-Milnes, PhD, Frank Porreca, PhD, Todd Vanderah, PhD |
|
2021 |
Decreased dopaminergic inhibition of pyramidal neurons in anterior cingulate cortex maintains chronic neuropathic pain. |
Edita Navratilova, Frank Porreca, PhD |
